$8.30
1.07%
NYSE, Aug 29, 11:20 pm CET
ISIN
US29089Q1058
Symbol
EBS

Emergent Biosolutions Inc Stock price

$8.30
+1.80 27.69% 1M
+0.82 10.96% 6M
-1.26 13.18% YTD
-0.61 6.85% 1Y
-16.31 66.27% 3Y
-105.75 92.72% 5Y
-23.14 73.60% 10Y
-2.75 24.89% 20Y
NYSE, Closing price Fri, Aug 29 2025
-0.09 1.07%
ISIN
US29089Q1058
Symbol
EBS
Industry

Key metrics

Basic
Market capitalization
$442.8m
Enterprise Value
$843.3m
Net debt
$400.5m
Cash
$267.3m
Shares outstanding
53.7m
Valuation (TTM | estimate)
P/E
3.2 | 6.9
P/S
0.5 | 0.6
EV/Sales
1.0 | 1.1
EV/FCF
5.4
P/B
0.8
Financial Health
Equity Ratio
34.7%
Return on Equity
-39.5%
ROCE
8.4%
ROIC
7.5%
Debt/Equity
1.2
Financials (TTM | estimate)
Revenue
$851.6m | $795.0m
EBITDA
$174.0m | $174.9m
EBIT
$108.9m | $75.1m
Net Income
$139.5m | $64.5m
Free Cash Flow
$155.0m
Growth (TTM | estimate)
Revenue
-22.7% | -23.8%
EBITDA
225.0% | 1,166.7%
EBIT
153.3% | 192.2%
Net Income
123.8% | 133.9%
Free Cash Flow
395.2%
Margin (TTM | estimate)
Gross
53.6%
EBITDA
20.4% | 22.0%
EBIT
12.8%
Net
16.4% | 8.1%
Free Cash Flow
18.2%
More
EPS
$2.6
FCF per Share
$2.9
Short interest
18.6%
Employees
900
Rev per Employee
$1.2m
Show more

Is Emergent Biosolutions Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Emergent Biosolutions Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Emergent Biosolutions Inc forecast:

5x Buy
71%
1x Hold
14%
1x Sell
14%

Analyst Opinions

7 Analysts have issued a Emergent Biosolutions Inc forecast:

Buy
71%
Hold
14%
Sell
14%

Financial data from Emergent Biosolutions Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
852 852
23% 23%
100%
- Direct Costs 395 395
51% 51%
46%
457 457
52% 52%
54%
- Selling and Administrative Expenses 233 233
33% 33%
27%
- Research and Development Expense 50 50
46% 46%
6%
174 174
225% 225%
20%
- Depreciation and Amortization 65 65
0% 0%
8%
EBIT (Operating Income) EBIT 109 109
153% 153%
13%
Net Profit 140 140
124% 124%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Emergent Biosolutions Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Emergent Biosolutions Inc Stock News

Neutral
GlobeNewsWire
3 days ago
GAITHERSBURG, Md., Aug. 29, 2025 (GLOBE NEWSWIRE) -- In honor of International Overdose Awareness Day (IOAD) on August 31, Emergent BioSolutions (NYSE: EBS) is re-launching its Ready to Rescue public education campaign, which raises awareness of opioid emergencies and the importance of being prepared with NARCAN® Nasal Spray among young adults at college/university activations with Greek Life, ...
Neutral
GlobeNewsWire
5 days ago
GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's senior management team will participate in the following investor conferences: Wells Fargo 20 th Annual Healthcare Conference September 4, 20253:00 pm ETWebcast link here One-on-one meetings HCW 27 th Annual Global Investment Conference September 9, 20251:30 ...
Neutral
GlobeNewsWire
11 days ago
GAITHERSBURG, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- As opioid emergencies continue to be the leading cause of accidental death in the United States,1 Emergent BioSolutions (NYSE: EBS) is teaming up with Voices for Awareness and Facing Fentanyl Now in honor of National Fentanyl Prevention and Awareness Day™ on August 21, 2025. As part of this year's efforts, these leading advocacy organizations...
More Emergent Biosolutions Inc News

Company Profile

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Joseph Papa
Employees 900
Founded 1998
Website emergentbiosolutions.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today